Who Exports Rifampicin from India — 175 Suppliers Behind a $1.3B Market
India's rifampicin export market is supplied by 175 active exporters who collectively shipped $1.3B across 3,913 shipments. LUPIN LIMITED leads with a 62.5% market share, followed by MACLEODS PHARMACEUTICALS LTD and MACLEODS PHARMACEUTICALS LIMITED. The top 5 suppliers together control 98.9% of total export value, reflecting a concentrated market structure.
Top Rifampicin Exporters from India — Ranked by Export Value
LUPIN LIMITED is the leading rifampicin exporter from India, holding a 62.5% share of the $1.3B market across 3,913 shipments from 175 exporters. The top 5 suppliers — LUPIN LIMITED, MACLEODS PHARMACEUTICALS LTD, MACLEODS PHARMACEUTICALS LIMITED, MANEESH PHARMACEUTICALS LIMITED, SVIZERA LABS PRIVATE LIMITED — collectively control 98.9% of total export value, indicating a highly concentrated market. Individual shares are: LUPIN LIMITED (62.5%), MACLEODS PHARMACEUTICALS LTD (33.4%), MACLEODS PHARMACEUTICALS LIMITED (1.4%), MANEESH PHARMACEUTICALS LIMITED (1.1%), SVIZERA LABS PRIVATE LIMITED (0.5%).
Top Rifampicin Exporters from India
Ranked by export value · 175 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | LUPIN LIMITED RIFAMPICIN 150MG / ISONIAZID 75MG TABLETS.4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID,RIFAMPIN CAPSULES 300MG - 1BTLX60 CAPS | $843.6M | 58 | 62.5% |
| 2 | MACLEODS PHARMACEUTICALS LTD RIFAMPICIN 150MG / ISONIAZID 75MG TABLETS.RIFAMPICIN CAPSULES BP 150MG.4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID, | $450.4M | 124 | 33.4% |
| 3 | MACLEODS PHARMACEUTICALS LIMITED RIFAMPICIN 150MG / ISONIAZID 75MG TABLETS.RIFAMPICIN CAPSULES BP 150MG.4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID, | $18.5M | 87 | 1.4% |
| 4 | MANEESH PHARMACEUTICALS LIMITED 4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID,RIFAMPICIN 150MG+ISONIAZID 75MG+PYRAZINAMEDICINES. RIFAMPICIN 150MG+ISONIAZID 75 | $15.2M | 41 | 1.1% |
| 5 | SVIZERA LABS PRIVATE LIMITED 4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID, | $7.2M | 16 | 0.5% |
| 6 | OMNICALS PHARMA PRIVATE LIMITED | $4.2M | 5 | 0.3% |
| 7 | MANEESH PHARMACEUTICALS LTD 4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID,RIFAMPICIN 150MG+ISONIAZID 75MG+PYRAZINAMEDICINES. RIFAMPICIN 150MG+ISONIAZID 75 | $2.2M | 7 | 0.2% |
| 8 | SANDOZ PRIVATE LIMITED 4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID,RIFAMPICIN 150MG+ISONIAZID 75MG+PYRAZINAMEDICINES. RIFAMPICIN 150MG+ISONIAZID 75 | $1.5M | 11 | 0.1% |
| 9 | MEDWISE OVERSEAS PRIVATE LIMITED RIFAMPICIN 150MG+ISONIAZID 75MG+PYRAZINAMEDICINES. RIFAMPICIN 150MG+ISONIAZID 75MEDICINES. RIFAMPICIN 300MG+ISONIAZID 15 | $850.7K | 4 | 0.1% |
| 10 | COMBITIC GLOBAL CAPLET PRIVATE LIMITED | $803.7K | 2 | 0.1% |
| 11 | UNILINK PHARMA PRIVATE LIMITED | $710.5K | 2 | 0.1% |
| 12 | CENTURION LABORATORIES PRIVATE LIMITED | $432.4K | 1 | 0.0% |
| 13 | MICRO LABS LIMITED | $346.6K | 2 | 0.0% |
| 14 | DEUTSCHE LABS INC | $240.9K | 1 | 0.0% |
| 15 | PHAR & VIDE RIFAMPICIN 150MG / ISONIAZID 75MG TABLETS.RIFAMPICIN CAPSULES BP 150MG.4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID, | $236.0K | 2 | 0.0% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Rifampicin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| LUPIN LIMITED | Warning Letter, September | Unknown | Unknown | Not verified | FDA issued a warning letter citing CGMP violations at the Mandideep facility. |
| MACLEODS PHARMACEUTICALS LIMITED | Product Recall, February | Unknown | Unknown | Not verified | Voluntary recall of Losartan Potassium/Hydrochlorothiazide tablets due to NDEA i |
| GLENMARK PHARMACEUTICALS LIMITED | Warning Letter, July 2025 | Unknown | Unknown | Not verified | FDA cited inadequate investigations into dissolution failures for potassium chlo |
| INTAS PHARMACEUTICALS LIMITED | Warning Letter, November | Unknown | Unknown | Not verified | FDA observed CGMP violations, including data manipulation during visual inspecti |
| GLOBAL PHARMA HEALTHCARE PRIVATE LIMITED | Warning Letter, October 2 | Unknown | Unknown | Not verified | FDA cited significant CGMP violations at the Thiruporur facility. |
| UNEXO LIFESCIENCES PRIVATE LIMITED | Warning Letter, November | Unknown | Unknown | Not verified | FDA observed CGMP violations, including inadequate quality control oversight. |
| JAGSONPAL PHARMACEUTICALS LIMITED | Warning Letter, February | Unknown | Unknown | Not verified | FDA cited significant deviations from CGMP for APIs at the Bhiwadi facility. |
| NOVEL LABORATORIES, INC. D.B.A LUPIN | Warning Letter, June 2021 | Unknown | Unknown | Not verified | FDA observed CGMP violations, including inadequate cleaning procedures. |
TransData Nexus reviewed the regulatory standing of 8 leading Rifampicin exporters from India. 0 hold US FDA facility approvals, 0 maintain WHO-GMP certification, and 0 are EU GMP compliant. 7 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Rifampicin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. The city hosts more than 2,000 pharmaceutical companies, including major players like Dr. Reddy's Laboratories and Aurobindo Pharma. The establishment of Hyderabad Pharma City, recognized as a National Investment Manufacturing Zone in December 2019, further solidifies its position as a central hub for bulk drug manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations and biogenerics production. Gujarat accounts for 33% of India's drug manufacturing and 28% of drug exports, with Ahmedabad and Vadodara being pivotal centers. Notable companies such as Alembic Pharmaceuticals, headquartered in Vadodara, have a significant presence in this region.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products. Mumbai, being a major port city, facilitates the export of pharmaceuticals to various international markets. The region is home to several pharmaceutical companies that leverage its strategic location for global distribution.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives. The region attracts numerous pharmaceutical companies seeking cost-effective production solutions, contributing substantially to India's pharmaceutical output.
5Sourcing Recommendations
- Diversify Supplier Base: While LUPIN LIMITED and MACLEODS PHARMACEUTICALS LTD dominate Rifampicin exports, consider engaging with other suppliers to mitigate risks associated with supplier concentration.
- Leverage Regional Strengths: Utilize Hyderabad for bulk drug sourcing, Ahmedabad-Vadodara for formulations, and Mumbai-Thane-Raigad for export logistics to optimize the supply chain.
- Monitor Regulatory Compliance: Ensure all suppliers adhere to international quality standards and regulatory requirements to maintain product integrity and market access.
- Assess Market Dynamics: Regularly analyze export data and market trends to identify emerging opportunities and potential challenges in the Rifampicin supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Rifampicin exporters from India
LUPIN LIMITED — Lupin's subsidiary acquires nine brands from MNI in South Africa
Lupin's subsidiary, Pharma Dynamics, acquired nine brands from the Medical Nutritional Institute SA (MNI) in South Africa, through a partnership with ImpiloVest. The acquired brands address various health issues, aligning with Lupin's commitment to holistic and sustainable healthcare solutions. - IMPACT: This acquisition is unlikely to directly impact Lupin's Rifampicin exports, as the acquired brands focus on complementary and alternative medicines.
Impact: This acquisition is unlikely to directly impact Lupin's Rifampicin exports, as the acquired brands focus on complementary and alternative medicines.
LUPIN LIMITED — Lupin acquires UK-based Renascience Pharma for £12.3 million
Lupin Healthcare (UK) Limited, a wholly owned subsidiary of Lupin, acquired Renascience Pharma Limited, a UK-based pharmaceutical company, for £12.3 million. Renascience supplies niche branded bio-generic products in the UK, including injectables for infectious diseases. - IMPACT: The acquisition may enhance Lupin's portfolio in infectious diseases, potentially strengthening its position in the Rifampicin market.
Impact: The acquisition may enhance Lupin's portfolio in infectious diseases, potentially strengthening its position in the Rifampicin market.
LUPIN LIMITED — Lupin banks on complex generics, specialty products to sustain growth
Lupin announced a strategic focus on complex generics and specialty products, including respiratory therapies and targeted specialty acquisitions, to sustain growth in FY26–27. The company reported a 24% year-on-year rise in revenue in Q2 FY26, driven by strong gains in the United States and emerging markets. - IMPACT: This strategic focus may lead to increased investment in Rifampicin production, potentially boosting exports.
Impact: This strategic focus may lead to increased investment in Rifampicin production, potentially boosting exports.
Common Questions — Rifampicin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which rifampicin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, LUPIN LIMITED leads with 369 recorded shipments worth $843.6M. MACLEODS PHARMACEUTICALS LTD (1,280 shipments) and MACLEODS PHARMACEUTICALS LIMITED (387 shipments) are also established high-volume exporters.
Q How many rifampicin manufacturers are there in India?
India has 175 active rifampicin exporters with a combined export market of $1.3B across 3,913 shipments to 162 countries. The top 5 suppliers hold 98.9% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for rifampicin from India?
Average FOB unit price: $6.47 per unit, ranging from $0.00 to $192.43. Average shipment value: $344.9K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 175 verified Indian exporters of Rifampicin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,913 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 162 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,913 Verified Shipments
175 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists